[HTML] nature.comFull View

[HTML][HTML] Molecular determinants of response to PD-L1 blockade across tumor types

R Banchereau, N Leng, O Zill, E Sokol, G Liu…�- Nature�…, 2021 - nature.com
Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable clinical
responses in subsets of cancer patients across multiple indications, including non-small cell�…
Save Cite Cited by 104 Related articles

Molecular determinants of response to PD-L1 blockade across tumor types

R Banchereau, N Leng, O Zill, E Sokol…�- Nature�…, 2021 - ui.adsabs.harvard.edu
Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable clinical
responses in subsets of cancer patients across multiple indications, including non-small cell�…
Cite

Molecular determinants of response to PD-L1 blockade across tumor types.

R Banchereau, N Leng, O Zill, E Sokol, G Liu…�- Nature�…, 2021 - escholarship.org
Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable clinical
responses in subsets of cancer patients across multiple indications, including non-small cell�…
Cite

Molecular determinants of response to PD-L1 blockade across tumor types.

R Banchereau, N Leng, O Zill, E Sokol, G Liu…�- Nature�…, 2021 - europepmc.org
Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable clinical
responses in subsets of cancer patients across multiple indications, including non-small cell�…
Cite

Molecular determinants of response to PD-L1 blockade across tumor types

R Banchereau, N Leng, O Zill, E Sokol, G Liu…�- Nature�…, 2021 - ideas.repec.org
Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable clinical
responses in subsets of cancer patients across multiple indications, including non-small cell�…
Cite

Molecular determinants of response to PD-L1 blockade across tumor types

R Banchereau, N Leng, O Zill, E Sokol…�- Nature�…, 2021 - econpapers.repec.org
Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable clinical
responses in subsets of cancer patients across multiple indications, including non-small cell�…
Cite
[HTML] nih.gov

[HTML][HTML] Molecular determinants of response to PD-L1 blockade across tumor types

R Banchereau, N Leng, O Zill, E Sokol, G Liu…�- Nature�…, 2021 - ncbi.nlm.nih.gov
Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable clinical
responses in subsets of cancer patients across multiple indications, including non-small cell�…
Cite

Molecular determinants of response to PD-L1 blockade across tumor types

R Banchereau, N Leng, O Zill, E Sokol…�- Nature�…, 2021 - pubmed.ncbi.nlm.nih.gov
Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable clinical
responses in subsets of cancer patients across multiple indications, including non-small cell�…
Cite

Molecular determinants of response to PD-L1 blockade across tumor types.

R Banchereau, N Leng, O Zill, E Sokol…�- Nature�…, 2021 - search.ebscohost.com
Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable clinical
responses in subsets of cancer patients across multiple indications, including non-small cell�…
Cite

Molecular determinants of response to PD-L1 blockade across tumor types.

R Banchereau, N Leng, O Zill, E Sokol, G Liu…�- Nature�…, 2021 - europepmc.org
Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable clinical
responses in subsets of cancer patients across multiple indications, including non-small cell�…
Cite